LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-alpha/DAGL-beta inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation[1].
Molekulargewicht:
384.47
CAS Nummer:
[1800327-36-9]
Formel:
C25H24N2O2
Target-Kategorie:
DAGL
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
